Infliximab in psoriatic arthritis

Future Rheumatology

Volumn 2, Issue 1, 2007, Pages 13-22

  Anandarajah, Allen P ^a   Ritchlin, Christopher T ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Efficacy; Infliximab; Psoriatic arthritis; Tumor necrosis factor

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; AZATHIOPRINE; CYCLOSPORIN; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 12 ANTIBODY; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROTEIN P55; PROTEIN P75; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DRUG CLEARANCE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTHESITIS; HEPATITIS; HUMAN; LIVER FAILURE; LOW DRUG DOSE; LYMPHOMA; MONOTHERAPY; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; OSTEOLYSIS; PATHOPHYSIOLOGY; PHARYNGITIS; PHYSIOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS; SEIZURE; SHORT FORM 36; SIDE EFFECT; SINUSITIS; SYSTEMIC VASCULITIS; T LYMPHOCYTE; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 34249280965     PISSN: 17460816     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460816.2.1.13     Document Type: Article

References (59)

1. Anandarajah AP, Ritchlin CT: Treatment update on spondyloarthropathy. Curr. Opin. Rheumatol. 17, 247-256 (2005).
2. Gelfand JM, Gladman DD, Mease P et al.: Epidemiology of psoriatic arthritis in the United States population. J. Am. Acad. Dermatol. 53(4), 573 (2005).
3. Salonene SH: The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,990 members of European psoriasis patient associations. Proceedings of the Spring Symposium of the European Academy of Dermatology and Venereology. Malta, 27 February-1 March (2003).
4. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. J. Clin. Dermatol. 4, 441-447 (2003).
5. Boumpas DT, Illei GG, Tassiulas IO: Psoriatic arthritis. In: Primer On The Rheumatic Diseases 12th Edition. Klippel JH (Ed). The Arthritis Foundation, Atlanta, GA, USA 233-237 (2001).
6. McGonagle D, Marzo-Ortega H, Benjamin M, Emery P: Report on the second international; enthesitis Workshop. Arthritis Rheum. 48, 896-905 (2003).
7. Kane D, Stafford L, Bresnihan B et al.: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford). 42, 1460-1468 (2003).
8. Zachariae H, Zachariae R, Blomqvist K et al.: Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations: data from the Nordic Quality of Life Study. Acta Derm. Venereol. 82, 108-113 (2002).
9. Resnick DNG: Psoriatic Arthritis. WB Saunders (Ed). Philadelphia, PA, USA (1989).
10. Gladman DD, Shuckett R, Russel ML, Thorne JC, Schachter RK: Psoriatic arthritis (PsA) - an analysis of 220 patients. Q. J. Med. 62, 127-141 (1987).
11. Bruce I, Gladman DD: Psoriatic arthritis. Recognition and management. Biodrugs 9, 27-36 (1998).
12. Anandarajah AP, Ritchlin CT. Etanercept in psoriatic arthritis. Expert Opin. Biol. Ther. 3, 169-177 (2003).
13. Black RL, O'Brien WM, Van Scott EJ, Aurbach R, Eisen AZ, Bunim JJ: Methotrexate therapy in psoriatic arthritis; double-blind study on 21 patients. JAMA 189, 743-747 (1964).
14. Wilkens RF, Williams HJ, Ward JR et al.: Randomized, double-blind, placebo controlled trial of low dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 27, 376-381 (1984).
15. Clegg DO, Reda DJ, Abdellatif M: Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies; a Department of Veterans Affairs seronegative study. Arthritis Rheum. 42, 2325-2329 (1999).
16. Palit J, Hill J, Capell HA et al. A multicenter-double blind comparison of auranofin, intramuscular gold thiomalate and placebo in patients with psoriatic arthritis. Br. J. Rheumatol. 29, 280-283 (1990).
17. Carette S, Calvin A, McCafferty JP, Wallin BA: A double-blind placebo controlled study of auranofin in patients with psoriatic arthritis. Arthritis Rheum. 32, 158-165 (1989).
18. Levy J, Paulus HE, Barnett EV, Sokoloff M, Bangert R, Pearson CM: A double-blind controlled evaluation of azathioprine treatment in rheumatoid arthritis and psoriatic arthritis. Arthritis Rheum. 15, 116-117 (1972).
19. Steinsson K, Jonsdolttir I, Valdimarsson H: Cyclosporine A in psoriatic arthritis: an open study. Ann. Rheum. Dis. 49, 603-606 (1990).
20. Nash P, Clegg DO: Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann. Rheum. Dis. 64(Suppl. II), II74-II77 (2005).
21. Soriano ER, McHugh NJ: Therapies for peripheral joint disease in psoriatic arthritis. A systemic review. J. Rheumatol. 33, 1422-1430 (2006).
22. Kaltwasser JP, Nash P, Gladman D et al.: Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 50, 1939-1950 (2004).
23. Kavanaugh AF, Ritchlin CT, GRAPPA Treatment Guideline Committee et al.: Systemic review of treatments for PsA: an evidence based approach and basis for treatment guidelines. J. Rheumatol. 33, 1417-1421 (2006).
24. Bharat B, Aggarwal BB: Tumor necrosis factors receptor associated signaling molecules and their role in activation of apoptosis, JNK and NFκB. Ann. Rheum. Dis. 59(Suppl. I), I6-I16 (2000).
25. Anandarajah AP. Schwarz EM: Anti-RANKL therapy for Inflammatory bone disorders: mechanisms and potential clinical applications. J. Cell Biochem. 97, 226-232 (2006).
26. Anandarajah AP, Ritchlin CT: Pathogenesis of psoriatic arthritis. Curr. Opin. Rheumatol. 16, 338-343 (2004).
27. Partsch G, Steiner G, Leeb BF et al.: Highly increased levels of tumor necrosis factor-α and other proinflammatory cytokines in psoriatic arthritis in synovial fluid. J. Rheumatol. 24, 518-523 (1997).
28. Ritchlin C, Haas-Smith SA, Hick S et al.: Patterns of cytokine production in psoriatic synovium. J. Rheumatol. 25, 1544-4552 (1998).
29. Danning CL, Illei GG, Hitchon G et al.: Macrophage-derived cytokine and nuclear factor κ B p65 expression in synovial membrane and skin of patients with psoriatic arthritis. Arthritis Rheum. 43, 1244-1256 (2000).
30. Knight DM, Trinh H, Le J et al.: Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol. Immunology. 30, 1443-1453 (1993).
31. Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH. Infliximab treatment of rheumatoid arthritis and Crohn's disease. Ann. Pharmacother. 37, 1256-1265 (2003).
32. Scallon BJ, Arevalo Moore M, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-α monoclonal antibody cA2 binds recombinant transmembrane TNF-α and activates immune effector functions. Cytokine 7, 251-259 (1995).
33. Genovese MC, Cohen S, Moreland L et al.: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. 50, 1412-1419 (2004).
34. Antoni CE, Kavanaugh A, Kirkham B et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arhtiris. Arthritis Rheum. 52, 1227-1236 (2005).
35. Felson DT, Anderson JJ, Boers M et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38, 727-35 (1995).
36. Fredricksson T, Petersson U: Severe psoriasis - oral therapy with a new retinoid. Dermatologica 157, 238-244 (1978).
37. Kavanaugh A, Antoni CE, Gladman D et al.: The impact Study Group. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann. Rheum. Dis. 65, 1038-1043 (2006).
38. van der Heijde DM, van Leeuwen MA, van Riel PL, et al.: Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum. 35, 26-34 (1992).
39. Antoni CE, Krueger GG. de Vlam K et al.: Infliximab improves signs and symptoms of psoriatic arthritis; results of the IMPACT 2 trial. Ann. Rheum. Dis. 64, 1150-1157 (2005).
40. Kavanaugh A, Antoni CE, Krueger GG et al.: Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. Ann. Rheum. Dis. 65, 471-477 (2006).
41. Fries JF, Spitz PW, Young DY: The dimensions of health outcomes; the health assessment questionnaire, disability and pain scales. J. Rheumatol. 9, 789-93 (1982).
42. Ware JJ, Sherbourne CD: The MOS 36-ITEM short form health survey (SF-36). Conceptual framework and item selection. Med. Care 30, 473-83 (1992).
43. Canete JD, Pablos JL, Sanmart R et al.: Antiangiogenic effects of anti-tumor necrosis factor α therapy with infliximab in psoriatic arthritis. Arthritis Rheum. 50, 1636-1641 (2004).
44. Goedkoop ay, Kraan MC, Picavet DI et al.: Deactivation of endothelium and reduction in angiogenesis n psoriatic skin and synovium by low dose Infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res. Ther. 6: R326-R334 (2004).
45. Listing J, Strangfeld A, Kary S et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 52, 3403-3412 (2005).
46. Bongartz T, Sutton AJ, Sweeting MJ et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 295, 2275-2285 (2006).
47. Kroesen S, Widmer AF, Tyndall A et al.: Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF α therapy. Rheumatalogy (Oxford) 42, 617-621 (2003).
48. Gomex-Reino JJ, Carmona L, Valverde VR et al.: Treatment of rheumatoid arthritis with rumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum. 48, 2122-2127 (2003).
49. Wallis RS, Broder MS, Wong JY et al.: Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38, 1261-1265 (2004).
50. Sarzi-Puttini, Atzeni F, Doria A et al.: Tumor necrosis factor alpha, biologic agents and cardiovascular risk. Lupus 14, 780-784 (2005).
51. Reddy SM, Reed G, Anandarajah A et al.: Comparative analysis of disease activity, radiographic features and bone density in psoriatic and rheumatoid arthritis. Arthritis Rheum. 52, S640 (2005).
52. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J. Am. Acad. Dermatol. 54, 614-621 (2006).
53. Kyle S, Chandler D, Griffiths CEM et al.: Guideline for anti-TNF-α therapy in psoriatic arthritis. Rheumatology 44, 390-397 (2005).
54. Kavanaugh A. Pharmacoeconomic considerations in the treatment of psoriatic arthritis. Rheumatology 45, 790-791 (2006).
55. Brandt J, Haibel H, Reddig J et al.: Successful short term treatment of severe undifferentiated spondyloarthropathy with anti-tumor necrosis factor alpha monoclonal antibody infliximab. J. Rheumatol. 29, 118-122 (2002).
56. Jois RN, Leeder J, Gibb A et al.: Low-dose infliximab treatment for ankylosing spondylitis-clinically-and cost cost-effective. Rheumatology (2006).
57. Mease PJ, Kivitz AJ, Burch FX et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy and effect on disease progression. Arhtritis Rheum. 50, 2264-2271 (2004).
58. Mease PJ, Gladman DD, Ritchlin CT et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis. Arhtritis Rheum. 52, 3279-3289 (2005).
59. Mease PJ, Gladman DD, Keystone EC: Alefacept in combination with methotrexate for the treatment of psoriatic arthritis. Arhtritis Rheum. 54, 1638-1645 (2006).